Migraine is a common neurological disorder, which can produce significant disability, and reduce health-related quality of life.
Le JOURnAL CAnAdIen deS SCIenCeS neUROLOGIQUeS
Suppl. 3 -S5 workdays were lost annually in Canada due to migraine. 4 disability related to migraine has been recognized by the World Health Organization, which ranked migraine as 19th among all causes of disability in terms of years lived with disability. 6 The International Headache Society (IHS) has classified two major subtypes: migraine without aura, and migraine with aura. Migraine without aura is the most common migraine subtype, and is characterized by headache attacks lasting 4 to 72 hours. Headache attacks are usually accompanied by other symptoms including photophobia, phonophobia, nausea, and sometimes vomiting (for diagnostic criteria see Tables 1 and 2 ). Individuals with migraine with aura experience in addition reversible focal neurological symptoms, which usually precede the headache and last up to 60 minutes, or occasionally longer (Table 2 ). 7, 8 Acute (symptomatic) pharmacological migraine therapy refers to the use of medication to treat individual migraine attacks. The great majority of adults with migraine in Canada (90%) use acute medications for their migraine attacks. 2 Acute medications are, however, only one component of migraine treatment. Based on headache frequency in population studies, it would appear that up to 25% of migraine sufferers might also benefit from the use of daily preventive medications to reduce migraine frequency. 9 Pharmacological prophylaxis should be considered in patients with frequent and/or refractory migraine attacks. All migraine sufferers should also consider careful management of lifestyle factors and specific migraine triggers, which can potentially increase migraine frequency (see Headache network Canada website: http://www.headache network.ca (in english and French), Migraine Quebec website: www.migrainequebec.com (in French; to be translated into english), and American Headache Society website: http://www.americanheadachesociety.org/professionalresources/ TriggerAvoidanceInformation.asp). In addition, behavioural interventions including the mastery of relaxation techniques, stress management, pacing, cognitive behavioural therapy, and biofeedback have the potential to benefit many migraine sufferers. [10] [11] [12] Acute pharmacological migraine therapy includes both "migraine-specific" medications (e.g., triptans, dihydroergotamine), and "non-specific" medications (e.g., ASA, acetaminophen, nSAIds). It also includes adjunctive drugs such as anti-emetics (e.g., domperidone, metoclopramide, prochlorperazine) in oral or rectal formulations. The introduction of sumatriptan subcutaneous injection in 1991 represented a significant advance in the management of migraine. When the first Canadian migraine guidelines were published in 1997, the only triptan available was sumatriptan. 7 Since that time, six more triptans have become available to Canadians. Although triptans are generally considered to be the most effective of the acute migraine medications overall, as recently as 2005, only 8% of Canadians listed a triptan as their main migraine medication. 2 Under-utilization of effective acute therapies has the potential to negatively impact quality of life for migraine sufferers. Population-based data in 2005 indicated that at least 200,000 Canadian women with migraine were very unsatisfied with the effectiveness of their acute migraine medications. 2, 13 These guidelines have been developed to assist both health professionals and patients to develop more effective acute migraine treatment strategies. 
Guideline Objectives and Target Population

Objectives
The primary objective of this guideline is to assist the physician in choosing an appropriate acute medication for an individual with migraine, based on current evidence in the medical literature. An additional objective is to assist the practitioner in using the chosen medication in the most effective manner.
The main clinical question that this guideline aims to help answer for the medical practitioner is, "Which acute medication should be prescribed for an individual patient in a specific clinical situation?"
The ultimate purpose or goal of this guideline is to reduce the headache-related disability suffered by individuals with migraine.
Target population
This guideline provides evidence-based recommendations for the outpatient acute management of adults (18 years-of-age or older) with episodic migraine (patients who experience migraine headache attacks on less than 15 days/month). It does not include recommendations for pediatric patients and for the emergency room management of acute migraine.
Although it is likely that physicians will extrapolate from the evidence presented here and use it for the care of patients with chronic migraine (headache on 15 days a month or more, with diagnostic criteria for migraine met on at least eight days a month), many of the clinical trials reviewed for this guideline did not include patients with headache frequencies of this magnitude.
Who should use this guideline?
This guideline is intended primarily for physicians who treat patients with migraine, including both family physicians, and specialists. Other health professionals who treat patients with migraine may also find this guideline helpful. As migraine is a chronic disorder, and it is important that patients with migraine partner with their health care professionals in order to achieve the best management success possible, individuals with migraine and their families may also find this guideline useful.
Expert consensus and recommendations
The core of this guideline is Section 2 "Targeted Review: Medications for Acute Migraine Treatment". The recommendations in this section are based on a targeted review as described in that section. evidence from randomized controlled trials is not available, however, to guide clinicians with regard to all the clinical decisions that must be made. To recognize this, treatment suggestions made in other sections of this guideline are labeled as "expert consensus", as they are based on a general literature review and on the expert opinion of clinicians experienced in migraine treatment. These expert opinions were developed through expert consensus groups (See Appendix 1).
Goals of Acute Migraine Therapy
The goals of acute (or symptomatic) migraine therapy are to relieve pain and the associated symptoms of migraine (e.g., nausea, vomiting, photophobia, phonophobia) rapidly and consistently, with minimal or no adverse events, and to relieve migraine-related disability so that the patient can return quickly to normal function. 7 Although some patients may be able to achieve the goal of becoming pain-free within two hours of taking an acute medication, those who only achieve partial headache relief (pain reduction) should try at least several acute medications (including several triptans if not contraindicated) over time for different migraine attacks, to determine if it is possible for them to reach this goal.
General Principles of Acute Migraine Therapy
The response of the individual with migraine to a specific acute drug cannot be predicted with certainty
Response to acute medications is individual and idiosyncratic. 7 If the response to the first medication is not excellent, several medications may need to be tried (in succession) over time for different attacks to determine the most suitable medication in terms of efficacy and tolerability. Access to two different medications may be necessary if a patient suffers from attacks of varying severities. The choice of a particular symptomatic medication should take into account the efficacy of past treatments, and the presence of any concomitant disorders that may preclude use of certain medications. For patients with severe attacks, a rescue medication may be needed if their usual medication fails. 
EXPERT CONSENSUS
Early intervention: Most patients should be encouraged to take their acute medication early in the attack
To experience maximum effectiveness, patients should use acute medications as early as possible after headache onset, and while the pain is still mild. For the triptans, several prospective studies have shown improved efficacy with early treatment (see Table 6 in Section 2). Triptans may be more effective when taken early in the attack, because they can prevent but not reverse central sensitization. Central sensitization, as manifested by cutaneous allodynia, may occur in up to 75% of patients within 20 to 60 minutes of migraine onset. 14 When discussing early treatment, patients should be educated with regard to the effects of medication overuse, and the need to differentiate migraine attacks from tension-type headache. For patients with frequent migraine attacks, early treatment may need to be used very cautiously. More effective acute treatment may result in less symptomatic medication use; however, indiscriminate use of early treatment has the potential to lead to acute medication overuse in some patients. 15 Patients may find taking acute medication during the migraine aura useful to manage their headaches, but for triptans there is evidence that they are best taken at the onset of head pain rather than during the aura. This is particularly true for subcutaneous sumatriptan (see Section 3).
EXPERT CONSENSUS
i. Patients should be advised to take acute medications as early as possible during their migraine attacks while pain is still mild, unless at risk for medication overuse headache.
An appropriate treatment approach should be chosen
Three basic treatment strategies have been documented as options for acute migraine treatment. 16 In Section 3 of this guideline, we use the term "strategy" for acute treatment paradigms for specific patient groups, based on patient clinical features. To avoid confusion, we will therefore use the term "approach" rather than "strategy" for the more broad or generalized concepts of stratified and step care approaches to care, while recognizing that these were termed "strategies" in the original publications that described them: a. "Stratified care": The medication chosen for a patient is based on attack severity and/or degree of migraine-related disability. 17,18 b. "Step care within an attack": A simple analgesic or nSAId is used initially for a migraine attack. If the first medication is not successful, another medication (e.g., a triptan), is used a few hours later. c. "
Step care across attacks": The practitioner prescribes an initial medication (e.g., nSAId), and the patient tries this for several attacks. If this medication is not sufficiently effective, the practitioner would prescribe another medication (e.g., a triptan) for subsequent attacks.
In practice, many patients have tried several non-prescription medications prior to consulting a physician for their headaches; therefore, a "step care across attacks" approach is already in place when the physician prescribes a more effective medication.
"Stratified care" is likely to be the most effective acute treatment approach, and has been shown to be cost effective. 19 It has been promoted by several guidelines (The U.S. Headache Consortium 20 , and the european Federation of neurological Societies 21, 22 ). Stratified care is the model of care recommended here for patients with the most severe migraine attacks, while a modified or "hybrid" model of care, which incorporates features of both stratified care and the "step care across attacks" model, is recommended for most patients with migraine in this guideline (see Section 3). "
Step care within an attack" has been promoted by some guidelines, but it has the disadvantage that if the first medication fails, the second presumably more effective medication may fail as well, because it is taken later in the attack (at a time when it may no longer be as effective as it could have been if taken earlier). The "step care across attacks" approach has the potential disadvantage that if the initial medication provided by the physician is ineffective, patients may become discouraged and not pursue additional medical care for their migraine (become a "lapsed consulter"). If this approach is chosen, patients should be informed early of the remaining treatment options, so that they realize other therapies are available for their migraine should that prove necessary.
It needs to be recognized that many patients with migraine have more than one attack severity. If they are able to identify early in the attack whether they are going to experience a severe attack or one of lesser intensity, they may be able to choose an appropriate medication for their attack based on the stratified care model. If patients are unable to identify the ultimate severity of their migraine attack early in its course, a "step care within an attack" approach may be appropriate if the majority of their attacks are relatively mild and respond to an nSAId or other medication, and if their more severe attacks still respond to their second medication even when taken later in the attack. 
EXPERT CONSENSUS
A suitable medication formulation should be chosen
Patient preference needs to be considered when recommending a particular medication formulation. 23, 24 However, some formulations have advantages over others in specific clinical situations. For some patients, it may be advantageous to use one formulation for some attacks, and another formulation for others. a. For migraine attacks that build up very rapidly and/or are characterized by early vomiting, and for attacks that present full-blown upon awakening, an injectable formulation (e.g., subcutaneous sumatriptan) has the potential to be most effective. 25-27 b. Patients with nausea and those who vomit only later in the attack may find nasal spray formulations to be more helpful than oral formulations, as medications delivered by nasal spray are partially absorbed through the nasal mucosa. 23, 24, 28, 29 c. Patients with lesser degrees of nausea or nausea that is exacerbated by taking water, and those who wish to treat their attacks early in situations where water may not be readily available, may find the orally disintegrating tablets more useful than regular tablets which are swallowed. Orally disintegrating tablets do not have a faster onset of action, as they are not absorbed through the buccal mucosa, but rather are swallowed with saliva, and absorbed in gastrointestinal tract. 23,24,30 d. For patients without significant nausea, regular oral tablets, orally disintegrating tablets, nasal sprays and injections are all appropriate options. The injection formulation has the greatest efficacy, but higher cost and more discomfort. 26, 27 Because of partial nasal absorption, nasal spray formulations may have a slightly faster onset of action than tablets. 28, 29 The evidence for significant absorption through the nasal mucosa is strongest for zolmitriptan nasal spray. 31, 32 e. Some oral formulations are designed for faster drug delivery and onset of action, as compared to regular oral tablets. examples are diclofenac powder for oral solution, sumatriptan dF (fast dissolving) tablet, and others (e.g., effervescent ASA, liquid-containing nSAId preparations).
Patients should be made aware of these options where appropriate, so that those with migraine attacks that increase rapidly in intensity can take advantage of these special formulations if they wish to. 
EXPERT CONSENSUS
Medication overuse needs to be avoided because of the risk of medication overuse headache
All the commonly used acute medications have the potential to cause medication overuse headache (MOH) in patients with migraine when used too frequently over a period of several months or more. [33] [34] [35] To avoid MOH, commonly accepted recommendations are to: a. Limit use of acetaminophen, ASA, and nSAIds to a maximum of 14 days a month. 36,37 b. Limit use of triptans, ergotamine, opioids and combination analgesics to a maximum of 9 days a month. 36, 37 For patients taking medications from both classes, the important principle is for the patient to be free of acute medications at least 20 days a month. 36, 37 The International Headache Society (IHS) diagnostic Criteria indicate that patients taking both triptans and nSAIds should limit their use of these to a total of 9 days a month to avoid risk of MOH (http://ihs-classification.org/en/01_einleitung/03_anleitung/).
For patients with frequent attacks who are at risk of MOH, behavioural approaches to migraine management and prophylactic medications should be considered in addition to acute medications. 
EXPERT CONSENSUS
Two or more acute medications can be combined if necessary
Some patients may obtain better migraine attack relief if they take two or more acute medications simultaneously for their migraine attacks. For many patients, triptans satisfactorily treat migraine related nausea as well as the headache. Others, however, may benefit from taking an anti-nauseant (e.g., metoclopramide 10 mg) with their triptan. Some patients with attacks that do not respond satisfactorily to a triptan alone may have better relief if they take an nSAId (e.g., naproxen sodium 550 mg) with their triptan. These acute treatment options are discussed in more detail in Section 3 of the guideline.
EXPERT CONSENSUS i. Although a single acute medication may relieve migraine attacks satisfactorily for many patients, others may benefit from taking more than one medication simultaneously (e.g., an NSAID with an anti-nauseant; an anti-nauseant with a triptan, or a triptan with an NSAID).
Choosing an Acute Migraine Medication
There is no ideal acute migraine medication. Practitioners should find the principles of acute migraine therapy outlined above helpful in choosing an acute medication for a specific patient. Medication cost has not been directly considered in the recommendations in this guideline, although it is considered to some extent in the "combined acute medication treatment approach" in Section 3. In this approach, unless the patient has severe attacks and fits into the "stratified care" approach, less expensive nSAIds are tried before a triptan is chosen (if necessary) as the patient's primary acute medication.
In addition, other considerations in choosing an acute medication for a specific patient include:
1. efficacy: How strong is the evidence that the drug is effective in acute migraine therapy and how effective is it compared to other treatment options? 2. drug side effect profile: How safe is the drug, and how well tolerated? 3. Co-existing medical and/or psychiatric disorders: does the patient have another disorder that is a contraindication for some of the acute migraine medications (e.g., a history of peptic ulcer, or cardiovascular disease)? 4. Patient preference: Section 2 provides information on the evidence for efficacy and side effects of the various acute migraine medications. Further guidance in choosing an acute medication for a specific patient is given in Section 3. A patient survey has indicated that an overwhelming majority of patients consider complete relief of head pain, no recurrence, and rapid onset of action as important or very important attributes of acute migraine therapy. 38 Fortunately, many clinical trials use endpoints relevant to these preferences, and these are used in this guideline where possible.
